Developing a Broadly Applicable Therapeutic Strategy to Reverse Symptoms of Neurodevelopmental Disorders
One in six children in the US is afflicted by
Neurodevelopmental disorders (NDD), such as Autism, Down syndrome, and cerebral
palsy. In these NDD patients, genetic sequencing has discovered mutations in a
number of NDD risk genes. Interestingly, it has been demonstrated in lab mice
that using a gene therapy approach to replace mutant NDD risk genes can largely
alleviate symptoms in adults, which suggests that the brain abnormalities in
NDD caused by genetic mutations may be reversible even after disease onset.
Although there is an ongoing effort to develop gene therapy clinical trials
aiming to replace or correct mutations in NDD risk genes in patients to treat
disease symptoms, such gene therapies cannot be applied to the majority of NDD
patients who carry a broad range of mutations in one or multiple NDD risk
genes. Moreover, currently there is no effective drug therapies to treat such
devastating disorders.
In order to effectively treat a meaningful number of patients
in a cost-effective way, my team and I are devising a new therapeutic strategy
combining the benefits of both drug and gene therapies, which can be
standardized and applied to a broad range of NDD patients. Our group recently
made a surprising discovery that a number of drugs originally developed for
treating non-brain diseases such as leukemia could be repurposed into broadly
applicable NDD therapeutics. Applying candidate drugs to human brain cells and
mouse models of Rett syndrome, a severe form of NDD, corrected abnormalities in
gene expression and reduced epileptic seizure that is commonly associated with
many subtypes of NDD, suggesting these drugs’ exciting therapeutic potential.
We plan to further examine how our candidate drugs,
originally designed to treat non-brain diseases, exert therapeutic benefits on
brain cells. We will also test whether our candidate drugs can alleviate
symptoms in a number of preclinical NDD models carrying different risk gene
mutations. Our vision is to develop broadly applicable therapeutics that
relieve NDD symptoms regardless of the complexity or uncertainty of the causes,
similar to the way a pair of eyeglasses can improve vision in many myopia patients.